The invention provides for compounds that are HAT activators or inhibitors. The invention further provides a method for treating neurodegenerative diseases, cancer and other malignant conditions, or to increase memory in a subject not suffering from a neurodegenerative disease by administering HAT activators or inhibitors to a subject in need thereof. The method further comprises co-administration of HD AC inhibitors with HAT activators or HD AC activators with HAT inhibitors.

This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.

This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.

Disclosed are a high stress resistant plant growth regulator and a preparation and use thereof. In particular, the compound provided by the present invention is an ABA substitute for significantly improving the stress resistance of plants, and therefore has a very wide application prospect.

Disclosed are a high stress resistant plant growth regulator and a preparation and use thereof. In particular, the compound provided by the present invention is an ABA substitute for significantly improving the stress resistance of plants, and therefore has a very wide application prospect.

The present disclosure provides inhibitors of MIF tautomerase activity. In certain embodiments, the compounds inhibitors are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds are useful in reversing, ameliorating, and/or preventing angiogenesis.

The present disclosure provides inhibitors of MIF tautomerase activity. In certain embodiments, the compounds inhibitors are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds are useful in reversing, ameliorating, and/or preventing angiogenesis.

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

A platform drug delivery system and a method of improving the delivery of low solubility pharmaceuticals utilizing crystal engineering and Theanine dissolution resulting in enhanced bioactivity, dissolution rate, and solid state stability.

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.